Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose–response meta-analysis

Author

Year

Region

Follow-up (month)

Age (year)

No. (M/F)

Sample size

Outcome

Cut-off value

NOS score

Porrata et al. [28]

2010

USA

59.1 (13.9–107.8)

64 (20–92)

146/109

255

OS, PFS

3.5

8

Ho et al. [11]

2015

China

53.28

61.0 (16–88)

80/68

148

OS, PFS

2.11

7

Keam et al. [23]

2015

Korea

59.0 (2.5–118.5)

61 (16–87)

226/221

447

OS, PFS

3

8

Melchardt et al. [9]

2015

Austria

53

65.3 (20–92)

270/245

515

OS

5.54

8

Ming et al. [29]

2015

China

NR

55 (20–85)

24/27

51

OS

2.32

6

Hong et al. [22]

2016

Korea

48.9 (46.5–51.3)

56 (16–86)

177/136

313

PFS

2.42

8

Ni et al. [27]

2016

China

NR

54 (14–75)

36/23

59

OS, PFS

2.915

6

Periša et al. [25]

2016

Croatia

27 (1–105)

63 (22–87)

51/66

117

OS, EFS

2.63

6

Wang et al. [26]

2016

China

29 (2–122)

NR

90/66

156

OS, PFS

3.0

6

Park et al. [24]

2016

Korea

NR

60 (32–81)

53/46

99

OS, PFS

3.5

6

Wang et al. [8]

2017

China

NR

54 (18–86)

202/153

355

OS, PFS

2.81

7

  1. NR not reported, OS overall survival, PFS progression free survival, EFS event free survival, NOS Newcastle–Ottawa Quality Assessment Scale